BioTuesdays

Author - Michelle Carr

soliton
Markets

Roth starts Soliton at buy; PT $14

Roth Capital Partners launched coverage of Soliton (NASDAQ:SOLY) with a “buy” rating and $14 price target. The stock closed at $8.80 on March 26. Soliton is an aesthetic company that utilizes acoustic pulse technology...

March 27, 2020
atyr Pharma
Markets

HCW cuts aTyr Pharma to neutral and removes PT

H.C. Wainwright downgraded aTyr Pharma (NASDAQ:LIFE) to “neutral” from “buy” and removed its price target, citing delays in topline results from a Phase 1b/2a trial of ATYR1923 for the treatment of sarcoidosis, an...

March 27, 2020
Eyenovia
Markets

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

March 26, 2020
Novavax
Markets

Ladenburg ups Novavax PT to $24 from $16

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $24 from $16 after the company reported impressive pivotal results with its lead asset, NanoFlu. The stock closed at $12.77 on March 24. Analyst...

March 25, 2020
iBio Inc.
Developments

iBio Joins the Alliance for Biosecurity

iBio (NYSE AMERICAN:IBIO) joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies, along with laboratory and academic partners, that promote a strong public-private partnership in order to ensure...

March 20, 2020
Markets

BTIG cuts ViewRay to neutral and removes PT

BTIG downgraded ViewRay (NASDAQ:VRAY) to “neutral” from “buy” and removed its price target after the company’s 2020 revenue guidance of $58-million to $95-million was “well below even the lowest Street estimates.” The...

March 13, 2020
electroCore
Markets

HCW starts electroCore at buy; PT $2

H.C. Wainwright initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $2 price target. The stock closed at 65 cents on March 9. electroCore is commercializing its lead product, gammaCore, the only FDA...

March 10, 2020
Eloxx Pharma
Markets

HCW slashes Eloxx Pharma PT to $3 from $10

H.C. Wainwright slashed its price target for Eloxx Pharmaceuticals (NASDAQ:ELOX) to $3 from $10 and retained its “neutral” rating, saying the strength of the company’s ELX-02 program in cystic fibrosis is yet to be...

March 6, 2020